TrialHaematologica2024

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.

Christopher R Flowers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.